Immune checkpoint inhibitors (ICIs) can block the interaction between PD-1 and PD-L1, promote the immune system to kill tumor cells (1, 2), and have been proven to be effective in treating metastatic and/or recurrent cervical cancer. This evidence concerns the gene CD274 and cervical cancer.